MacBook Air Flexgate is an unofficial name increasingly used for screen problems that appear when the laptop lid reaches a particular angle. The display may flicker, lose its backlight, show colored lines or turn completely black even though the computer continues running.

The term can be misleading. The original Flexgate controversy involved certain 13-inch MacBook Pro models from 2016, not MacBook Air. Apple later created a display backlight service program for eligible MacBook Pro units after determining that a small percentage could develop uneven lighting or lose the backlight entirely.

No equivalent MacBook Air repair program currently appears among Apple active service programs. Individual Air models can still experience failures involving display cables, connectors, backlight components or the LCD panel, but that does not establish one confirmed defect affecting every generation.

Owners therefore need to identify the symptom before assuming the screen has the same problem associated with the earlier MacBook Pro.

MacBook Air Flexgate Is Not the Original Flexgate

MacBook Air Flexgate usually refers to damage or wear affecting the thin cables carrying display information and power between the computer body and the screen.

These cables must flex every time the lid opens or closes. When a cable, connector or bonded section begins failing, the problem may initially appear only at certain screen angles. Moving the lid can restore the image temporarily, followed by another blackout when the display opens farther.

The original MacBook Pro issue became associated with a short backlight cable integrated into the display assembly. Repeated movement could place stress on the cable, producing a stage-light effect along the bottom of the screen before the backlight eventually stopped working.

MacBook Air designs also use compact display connections routed through the hinge area, but the internal construction differs across generations. A cable-related Air failure should not automatically be treated as evidence that Apple reused the exact defective MacBook Pro component.

The distinction matters during repair. A technician may use “Flexgate” as convenient shorthand, while the written diagnosis may identify a damaged display cable, backlight circuit, panel connection or complete display assembly.

Customers should ask which component has failed and how the conclusion was reached rather than accepting the nickname as the diagnosis.

Which MacBook Air Models Are Mentioned Most

Reports of angle-dependent MacBook Air display failures most commonly involve Retina models introduced from 2018 onward.

The 2018 and 2019 Intel MacBook Air share a thin Retina design with display connections running through the hinge area. The early 2020 Intel version and late 2020 M1 MacBook Air use closely related chassis designs, making symptoms across these machines look similar even when the failed component is not identical.

Owners describe displays that work when opened slightly but flicker, develop lines or turn black when moved toward a normal viewing position. Some units recover after the lid is partly closed, strongly suggesting a physical connection affected by movement.

The M1 MacBook Air receives particular attention because it sold in large numbers and remained available for several years. A greater number of public complaints does not necessarily mean it has a higher failure rate, but many of these computers are now old enough for wear, accidental pressure and repeated hinge movement to become relevant.

The redesigned M2 MacBook Air introduced in 2022 uses a different enclosure and display assembly. M3 and later versions continue that flatter design. Individual screen and cable failures can occur, but there is no established evidence of a single Flexgate defect covering those generations.

Older wedge-shaped MacBook Air models released before the 2018 Retina redesign can also develop display cable problems. They are not normally included in the Flexgate discussion because their screen architecture predates the MacBook Pro controversy and their failures follow different repair patterns.

The exact model can be checked through:

Apple menu > About This Mac

The model year and screen size are more useful than the date the Mac was purchased. Retailers may sell an earlier generation long after its original release.

How to Recognize a Display Cable Failure

A strong Flexgate-style symptom is a display that changes immediately when the lid moves.

The screen may operate normally below a particular angle, then flicker or disappear as it opens farther. Returning the lid to the previous position restores the picture without restarting the Mac.

Uneven illumination along the bottom edge can point toward a backlight connection. Several bright or dark patches resembling stage lights are especially associated with cable or backlight distribution problems.

A completely dark screen may still contain a faint image. Shining a flashlight toward the display in a dark room can sometimes reveal the desktop beneath the failed backlight. This test should be performed gently without pressing against the panel.

Colored vertical lines, black bands or duplicated images can involve the display data connection, but they may also indicate panel damage. Lines that remain unchanged at every lid angle are less characteristic of a flex-related failure.

Cracks do not always appear on the outer glass. Pressure from a webcam cover, keyboard protector, plug, pen or other object left between the keyboard and display can damage the internal LCD while leaving the surface relatively smooth.

Liquid exposure may create lines, discoloration or intermittent operation around the hinge and display connectors. In those cases, repeatedly opening the lid can spread contamination or worsen damaged connections.

An external monitor provides one of the most useful tests. When the external image remains normal while the built-in screen fails, the graphics processor is probably still generating the picture correctly. Attention then moves toward the internal display assembly, cable or connector.

A screenshot can provide another distinction. Capture the screen while the fault is visible, then inspect the file on another device or external monitor. When the screenshot looks normal, the problem is likely occurring after macOS generates the image.

What Owners Should Do Before Paying for Repair

Back up the Mac as soon as an intermittent display problem begins. A screen that works at one angle today may become completely unusable after another cable movement.

Avoid repeatedly opening and closing the lid to demonstrate the fault. Each movement can place further stress on an already damaged connection.

Record a short video showing the display at different angles. Intermittent failures can disappear when a Mac reaches a repair counter, and clear documentation helps the technician reproduce the condition.

Apple Diagnostics may identify some hardware problems, although a clean result does not rule out a damaged display cable. Testing in macOS Recovery or during startup can help exclude an ordinary application problem.

Apple and authorized providers commonly replace the complete display assembly when the cable is integrated with the screen. That approach can make an out-of-warranty repair expensive even when the visible fault involves a small cable.

Independent repair specialists may offer component-level cable work for certain models. The quality and durability of those repairs vary considerably, and newer Air displays can require specialized equipment, adhesives and calibration.

Before authorizing work, request a written estimate identifying the model, suspected component, warranty on the repair and whether the replacement display is new, used, refurbished or genuine.

AppleCare+ may reduce the cost when coverage remains active, particularly if the screen shows accidental damage. Standard warranty coverage depends on the diagnosis and whether Apple determines that impact, liquid or external pressure caused the failure.

The current Apple service-program list should also be checked before paying. A MacBook Air display program could be introduced or changed later, while consumer-protection laws may provide additional rights in some countries even after the limited warranty ends.

Owners using the Mac with an external monitor can often continue working while evaluating repair options. FileVault credentials, backups and any essential recovery codes should be confirmed before service because a technician may need to erase, reset or retain the computer during inspection.

The post MacBook Air Flexgate Can Become a Costly Screen Failure appeared first on AppleMagazine.

A groundbreaking discovery at the University of California, Los Angeles (UCLA) has unveiled a promising new therapeutic avenue for kidney regeneration, leveraging a drug initially designed to repair heart tissue following myocardial infarction. This drug, known as AD-NP1, targets a specific protein—ENPP1—that plays a critical role in impeding the body’s natural healing processes in injured tissues. The revelation that AD-NP1 can also accelerate kidney repair heralds a significant advancement in regenerative medicine, especially for patients suffering from chronic kidney disease (CKD), a condition that affects millions globally.

The heart of this research revolves around a protein named ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1). When tissues such as the heart or kidney sustain injury, ENPP1 production escalates, initiating a cascade of metabolic disturbances that hinder energy synthesis within cells. This disruption compromises cellular function and ultimately stalls effective tissue regeneration. In the context of the kidney, which is vital for maintaining systemic homeostasis, such impediments can lead to progressive scarring and functional decline, culminating in kidney failure.

Through years of meticulous experiments, the UCLA team delineated the detrimental impact of ENPP1 on the kidney’s reparative capacity. They observed that injured renal tissue upregulates ENPP1 expression, which in turn resets the metabolic landscape of cells in the damaged microenvironment. This altered metabolic signaling disrupts mitochondrial function, thereby curtailing ATP production essential for cell proliferation and repair. By employing genetic knockout models in mice, where ENPP1 expression was inhibited, the researchers documented a striking enhancement in renal recovery post-injury. These mice demonstrated reduced fibrotic scarring and improved renal biomarkers, signaling restored kidney function.

Central to translating these findings into potential clinical interventions is AD-NP1, a sophisticated monoclonal antibody engineered to specifically neutralize ENPP1. Unlike broad-spectrum immunosuppressants or anti-inflammatory agents, AD-NP1 offers targeted therapeutic precision by binding solely to human ENPP1, circumventing off-target effects. Initially conceptualized to mitigate cardiac fibrosis and promote myocardial regeneration following heart attacks, AD-NP1’s mechanism exerts a similar rejuvenating influence on kidney tissues. The antibody effectively halts the ENPP1-induced metabolic sabotage, facilitating an environment conducive to cellular proliferation and tissue repair.

In experimental paradigms, the administration of AD-NP1 in mice subjected to nephrotoxic diets and chemically induced renal injuries yielded compelling outcomes. Within merely seven days of treatment, subjects exhibited marked improvements in kidney function tests and histological assessments showed diminished collagen deposition and scarring. These findings underscore the drug’s potential to transform the management of acute and chronic kidney injuries by reinstating the organ’s intrinsic regenerative programs, which are often stifled in disease states.

Moreover, the team’s translational approach integrated analyses of human kidney biopsies acquired from individuals with chronic kidney disease. These samples consistently manifested elevated ENPP1 levels relative to healthy controls, substantiating the protein’s pathological role in human renal disorders. This correlation not only reinforces the relevance of the preclinical models used but also paves the way for clinical evaluation of AD-NP1’s efficacy in human subjects suffering from renal ailments.

The broader implications of this discovery extend into the metabolic regulation of tissue repair. ENPP1’s role appears multifaceted, orchestrating cellular energy dynamics and intercellular communication networks that dictate regenerative outcomes. Inhibiting this protein intervenes in maladaptive signaling cascades, thereby restoring bioenergetic balance and enabling clonal expansion of healthy cells adjacent to injury sites. This paradigm shift in understanding organ regeneration emphasizes metabolic modulation as a cornerstone of effective healing strategies.

Prior to this research, the therapeutic targeting of ENPP1 was primarily confined to cardiac medicine. The successful repurposing of AD-NP1 for kidney injury illustrates the concept of cross-organ regenerative mechanisms, where molecular pathways governing tissue healing are conserved albeit contextually modulated. This discovery propels the field into a new frontier, advocating for the exploration of shared regenerative targets that can be manipulated across diverse organ systems.

AD-NP1’s journey into clinical trials commenced recently with FDA approval of a Phase 1 safety study in human patients recovering from heart attacks. This milestone reflects the rigorous preclinical validation of the drug’s pharmacodynamics and safety profile. Building on these milestones, ongoing efforts at UCLA aim to extend these trials to include patients with progressive kidney disease, setting the stage for comprehensive evaluation and potential future clinical application.

Underlying this innovative research are substantial investments from the National Institutes of Health, California Institute of Regenerative Medicine, and the U.S. Department of Defense. This underscores the strategic importance and translational potential of regenerative medicine therapies in addressing chronic diseases that impose heavy societal burdens. The interdisciplinary collaboration among cardiovascular scientists, nephrologists, and molecular biologists at UCLA exemplifies the synergy needed to unlock complex biological processes for therapeutic gain.

In summation, the identification of ENPP1 as a metabolic gatekeeper that impedes tissue repair, combined with the development of AD-NP1 to neutralize its effects, represents a significant leap forward in regenerative medicine. The drug’s ability to foster organ regeneration by restoring metabolic and cellular homeostasis offers hope for millions afflicted by kidney disease and opens novel avenues for organ repair strategies. As clinical trials progress, the scientific community eagerly anticipates further validation of these findings, potentially heralding a new era where molecularly targeted therapies can substantially reverse organ damage and restore quality of life.

Subject of Research: Kidney regeneration, metabolic regulation of tissue repair, ENPP1 protein inhibition, monoclonal antibody therapy

Article Title: UCLA Researchers Discover Novel Role for ENPP1 Inhibition in Enhancing Kidney Repair via AD-NP1

News Publication Date: Not specified (based on provided content)

Web References: Cell Stem Cell Journal Article

Keywords: ENPP1, kidney injury, chronic kidney disease, tissue regeneration, monoclonal antibody, AD-NP1, metabolic signaling, renal repair, fibrosis, UCLA, regenerative medicine, Phase 1 clinical trial

In the ongoing battle against prostate cancer, one of the most formidable obstacles researchers and clinicians face is the cancer cells’ remarkable ability to develop resistance to treatments. These malignant cells employ sophisticated adaptive mechanisms to survive the onslaught of therapeutic agents, rendering many promising drugs less effective over time. A groundbreaking study led by Dr. Noel Warfel and his team at the MUSC Hollings Cancer Center has uncovered a hitherto unrecognized pathway that explains why certain protein-targeting drugs falter, offering fresh hope for more potent and durable therapies. Published in the latest issue of Cancer Letters, this research not only elucidates a novel survival mechanism in prostate cancer cells but also proposes an innovative therapeutic strategy to circumvent drug resistance.

At the heart of this discovery lies PIM1, a serine/threonine kinase well-known for its role in promoting prostate tumor growth, survival, and resistance to conventional therapies. Despite the development of various PIM1 inhibitors aimed at curbing its kinase activity, clinical success has been elusive, particularly in patients with solid tumors. The study probes the inadequacies of these conventional inhibitors and shifts the focus towards understanding the multifaceted biology of PIM1. Dr. Warfel’s work reveals that simply inhibiting PIM1’s enzymatic function does not fully neutralize its cancer-supporting properties, as the protein wields influence beyond its traditional kinase signaling.

Classically, kinase inhibitors designed to target PIM1 have been intended to block its enzymatic activity—effectively halting the phosphorylation events that drive tumor progression. However, Warfel’s team discovered that these drugs paradoxically cause an accumulation of PIM1 protein within cancer cells. Rather than being degraded, the surplus protein lingers and continues to facilitate cancer cell survival through kinase-independent mechanisms. This phenomenon results in a paradoxical biological double-edged sword: while inhibiting the enzyme’s catalytic function, the drugs inadvertently empower cancer cells with a fresh lifeline to resist death.

Key to this newly uncovered survival mechanism is the interaction between PIM1 and another protein known as HMGB1, a chromatin-binding factor usually confined to the nucleus. HMGB1 has a pivotal role in orchestrating cellular responses to DNA damage, but when PIM1 protein is abundant, these two form a complex that relocates HMGB1 from the nucleus to the cytoplasm. Once in the cytoplasm, HMGB1 ignites autophagy—a cellular recycling process that allows cancer cells to eliminate dysfunctional organelles, particularly damaged mitochondria.

Damaged mitochondria are notorious sources of reactive oxygen species and oxidative stress, conditions that can precipitate cell death. By facilitating the clearance of these harmful mitochondria, the PIM1-HMGB1 axis effectively lowers oxidative stress, bestowing cancer cells with a remarkable resilience against therapies designed to induce lethal damage. This mitophagy-driven defense mechanism enables prostate cancer cells to survive treatment regimens that would otherwise be effective, thus revealing a sophisticated layer of therapeutic evasion.

The implications of these findings are profound. They underscore a fundamental flaw in the current approach to drug design for kinase targets: the assumption that merely inhibiting the catalytic activity of a protein suffices to halt its oncogenic functions. Dr. Warfel emphasizes that the presence of the PIM1 protein itself—irrespective of its enzymatic activity—can sustain drug resistance, signaling a need for therapies that eliminate the protein entirely rather than merely neutralizing its kinase function.

In response to this challenge, the research team previously engineered a novel class of molecules known as proteolysis-targeting chimeras (PROTACs), specifically designed to induce the degradation of the PIM1 protein. Their lead compound, PIMTAC, capitalizes on the cell’s own proteasomal machinery to selectively tag and destroy PIM proteins, rather than simply inhibiting their kinase activity. Laboratory experiments and mouse model studies demonstrate that PIMTAC significantly enhances cancer cell death by increasing oxidative stress and disrupting the HMGB1-mediated survival pathway, outperforming conventional PIM1 inhibitors.

PIMTAC’s capacity to degrade PIM1 addresses both the signaling-dependent and -independent functions of the protein, offering a more comprehensive treatment strategy. By eliminating the kinase-independent survival effects, this approach holds promise for overcoming the persistent issue of drug resistance that hampers the efficacy of current therapies. The data suggest that this novel method could extend beyond prostate cancer to other malignancies where PIM proteins contribute to disease progression, including breast, lung, and various hematologic cancers.

While the development of PIMTAC represents a significant advance, the research remains in its preclinical phase. Challenges such as optimizing systemic delivery of the relatively large PROTAC molecule and improving its tumor-targeting specificity need to be addressed before clinical trials can commence. However, the insights gleaned from these studies reaffirm the importance of in-depth biological exploration of cancer targets, even those that have been the focus of research for many years.

This work also reflects a broader paradigm shift in oncology drug development. Increasing recognition of non-catalytic roles played by kinases and other oncogenic proteins suggests a future where protein degradation technologies might supersede traditional enzyme inhibition. Dr. Warfel envisions a landscape in which cancer therapeutics not only disable protein functions but remove the underlying protein itself, thereby dismantling multiple cancer-supportive mechanisms simultaneously.

Ultimately, this study epitomizes the continuous innovation and relentless inquiry needed to outsmart cancer’s adaptability. By uncovering a concealed survival pathway and offering a way to dismantle it, researchers add a crucial weapon to the anticancer arsenal. For patients battling advanced prostate cancer, particularly those facing the frustrations of treatment resistance, such advances kindle hope for more effective, durable therapies that can translate to improved outcomes and prolonged survival.

The journey from laboratory breakthrough to clinical application involves numerous hurdles, but endeavors like Dr. Warfel’s offer a compelling blueprint for future cancer research. Exploring the nuanced biology of proteins like PIM1 not only deepens scientific understanding but also fuels the creation of revolutionary treatments with the potential to save lives. This study stands as a testament to the power of reexamining established targets with fresh eyes and cutting-edge techniques, underscoring the importance of basic and translational research in reshaping cancer therapy.

As the medical community continues to explore the complexities of tumor biology, the integration of protein-targeting strategies such as PROTACs will likely play an instrumental role in overcoming therapeutic resistance. The PIM1-HMGB1 interaction and its influence on mitophagy highlight how intricate and multifaceted cancer cell survival mechanisms can be. Future investigations will undoubtedly build upon this foundational work, expanding the horizon of possibilities for precise, effective, and personalized cancer treatment modalities.

---

Subject of Research: Cells

Article Title: Kinase-independent signaling by PIM1 promotes drug resistance by increasing mitophagy and reducing oxidative stress

News Publication Date: 27-May-2026

Web References:

• Cancer Letters Article: https://www.sciencedirect.com/science/article/pii/S0304383526003745
• Previous related work: https://www.mdpi.com/2073-4409/11/6/1006

References: DOI: 10.1016/j.canlet.2026.218611

Image Credits: Medical University of South Carolina, Photo by Clif Rhodes

Keywords: Kinase inhibitors, Prostate cancer, Autophagy

A former NASA engineer named John Muratore sat on console as launch director in early September 2016 as propellant flowed onto a Falcon 9 rocket in Florida. Ahead of a planned launch two days later, SpaceX was preparing for a static fire test of the vehicle.

Then, all of a sudden, the rocket exploded. "It came out of nowhere, and it was really violent," Muratore said. This fireball resulted in the destruction of the rocket, much of its launch site, and the AMOS-6 satellite already attached to the vehicle.

Nearly a decade later, on May 28, Blue Origin conducted a static fire test of a new rocket, with its larger New Glenn vehicle a few miles down the Florida coast. The company had gotten further into its test, reaching engine ignition, before its rocket also exploded.

Read full article

Comments

© USLaunchReport